Publications

Ajayi D.T, Orherhe O.M, Pillai G.C, Mouksassi S, Steffens B, Bräm D, Sprecher V, Hofmann D, Buettcher M, Coulibaly J.T, Ali S.M, Keiser J, Pfister M. Pharmacometric analysis to describe pharmacokinetics and exposure-efficacy response of ivermectin in adolescents infected with Trichuris trichiura. J Clin Pharmacol. 2025;65(4):433-440. DOI: 10.1002/jcph.6158

D'Abbrunzo I, Gigli L, Demitri N, Sabena C, Nervi C, Chierotti M.R, Bertoni S, Skoric I, Häberli C, Keiser J, Hasa D, Perissutti B. Higher-order multicomponent crystals as a strategy to decrease the IC50 parameter: the case of praziquantel, niclosamide and acetic acid. J Drug Deliv Sci Technol. 2025;109:106974. DOI: 10.1016/j.jddst.2025.106974

Dupouy B, Karpstein T, Häberli C, Cal M, Rottmann M, Mäser P, Keiser J, Elhabiri M, Davioud-Charvet E. Synthesis of 1,2,3-triazole-methyl-menadione derivatives: evaluation of electrochemical and antiparasitic properties against two blood-dwelling parasites. ChemMedChem. 2025;20(6):e202400731. DOI: 10.1002/cmdc.202400731

Dziwornu G.A, Attram H.D, Häberli C, Masike K, Njoroge M, Keiser J. Benzimidazole analogues active against adult Schistosoma mansoni: SAR analyses, in vivo efficacy in mice, and preliminary mechanistic studies as potential inhibitors of hemozoin formation. Eur J Med Chem. 2025;284:117186. DOI: 10.1016/j.ejmech.2024.117186

Fabbrizi E, Hailu G.S, Ganesan A, Fioravanti R, Zwergel C, Lambona C, Valente S, Fianco G, Iuzzolino A, Trisciuoglio D, Caroli J, Mattevi A, Häberli C, Keiser J, Rotili D, Mai A. Tranylcypromine-based LSD1 inhibitors as useful agents to reduce viability of Schistosoma mansoni. ACS Infect Dis. 2025;11(8):2178-2189. DOI: 10.1021/acsinfecdis.5c00224

Hattendorf J, Keiser J. Chasing the end of helminths: is elimination within reach?. Lancet. 2025;406(10502):420-422. DOI: 10.1016/s0140-6736(25)01094-3

Karpstein T, Kalamatianou A, Keller S, Späne P, Häberli C, Odermatt A, Blacque O, Cariou K, Gasser G, Keiser J. Synthesis and multidisciplinary preclinical investigations of ferrocenyl, ruthenocenyl, and benzyl derivatives of thiabendazole as new drug candidates against soil-transmitted helminth infections. ACS Infect Dis. 2025;11(7):2037-2047. DOI: 10.1021/acsinfecdis.5c00340

Kouamé N.A, Bär M, Kouadio J.N, Touré S, Keiser J, Coulibaly J.T. Prevalence and risk factors of soil-transmitted helminths in humans and domestic animals in southern Côte d'Ivoire. BMC Infect Dis. 2025;25:983. DOI: 10.1186/s12879-025-11099-8

Lo N.C, Addiss D.G, Buonfrate D, Amor A, Anegagrie M, Bisoffi Z, Bradbury R.S, Keiser J, Kepha S, Khieu V, Krolewiecki A, Mbonigaba J.B, Muñoz J, Mutapi F, Novela V, Vaz Nery S, Coffeng L.E, de Vlas S.J, Bartoszko J, Moja L, Mupfasoni D, Montresor A. Review of the WHO guideline on preventive chemotherapy for public health control of strongyloidiasis. Lancet Infect Dis. 2025;25(3):e146-e152. DOI: 10.1016/s1473-3099(24)00595-4

Lotz C.N, Mrimi E.C, Schneeberger P.H.H, Ali S.M, Hattendorf J, Keiser J. Performance of real-time polymerase chain reaction and Kato-Katz for diagnosing soil-transmitted helminth infections and evaluating treatment efficacy of emodepside in randomized controlled trials. PLoS Negl Trop Dis. 2025;19(2):e0012872. DOI: 10.1371/journal.pntd.0012872

Lotz C.N, Schneeberger P.H.H, Concu M, Ali S.M, Mrimi E.C, Keiser J. Implementation of real-time PCR assays for diagnosing intestinal protozoa infections. Parasitol Res. 2025;124(4):40. DOI: 10.1007/s00436-025-08483-3

Malan D, Van Niekerk S, Häberli C, Keiser J, Van der Kooy F. In vitro antischistosomal activity of Artemisia species. Acta Trop. 2025;262:107535. DOI: 10.1016/j.actatropica.2025.107535

Panzner U, Utzinger J, Keiser J. Schistosomiasis: cercarial finding and recognizing of human hosts as a prerequisite of invasion. Clin Microbiol Rev. 2025(in press). DOI: 10.1128/cmr.00196-24

Schnoz A, Sprecher V.P, Biendl S, Hussein H.S, Najim S.O, Ali M.N, Mohammed I.S, Ali S.M, Hattendorf J, Keiser J. Efficacy and safety of moxidectin-albendazole combination therapy for Trichuris trichiura infections in school-aged children: a double-blind, randomised, controlled, superiority trial. Lancet Infect Dis. 2025(in press). DOI: 10.1016/s1473-3099(25)00344-5

Taylor L, Keiser J. Emodepside for strongyloidiasis: insights from parasite genetics - Authors' reply. Lancet Infect Dis. 2025(in press). DOI: 10.1016/s1473-3099(25)00465-7

Taylor L, Many S, Jeanguenat H, Hattendorf J, Sayasone S, Keiser J. Efficacy and safety of ascending doses of emodepside in comparison with ivermectin in adults infected with Strongyloides stercoralis in Laos: a phase 2a, dose-ranging, randomised, parallel-group, placebo-controlled, single-blind clinical trial. Lancet Infect Dis. 2025(in press). DOI: 10.1016/s1473-3099(25)00255-5

Ueberall M.E, Berchthold M, Häberli C, Lindemann S, Spangenberg T, Keiser J, Grevelding C.G. Merck Open Global Health Library in vitro screening against Schistosoma mansoni identified two new substances with antischistosomal activities for further development. Parasit Vectors. 2025;18:40. DOI: 10.1186/s13071-024-06648-0

Venkatesan A, Chen R, Bär M, Schneeberger P.H.H, Reimer B, Hürlimann E, Coulibaly J.T, Ali S.M, Sayasone S, Soghigian J, Keiser J, Gilleard J.S. Trichuriasis in human patients from Côte d'Ivoire caused by novel Trichuris incognita species with low sensitivity to albendazole/ivermectin combination treatment. Emerg Infect Dis. 2025;31(1):104-114. DOI: 10.3201/eid3101.240995

Brooker S.J, Keiser J, Bundy D.A.P. Soil-transmitted helminths (geohelminths). In: Farrar J,Hotez P.J,Junghanss T,Kang G,Lalloo D,White N.J,Garcia P.J, eds. Manson's Tropical Diseases, 772-796. Amsterdam: Elsevier, 2024. DOI: 10.1016/B978-0-7020-7959-7.00060-9

Cesar-Rodo E, Dupouy B, Häberli C, Strub J.M, Williams D.L, Mäser P, Rottmann M, Keiser J, Lanfranchi D.A, Davioud-Charvet E. Regioselective synthesis of potential non-quinonoid prodrugs of plasmodione: antiparasitic properties against two hemoglobin-feeding parasites and drug metabolism studies. Molecules. 2024;29(22):5268. DOI: 10.3390/molecules29225268

Davie T, Serrat X, Imhof L, Snider J, Štagljar I, Keiser J, Hirano H, Watanabe N, Osada H, Fraser A.G. Identification of a family of species-selective complex I inhibitors as potential anthelmintics. Nat Commun. 2024;15:3367. DOI: 10.1038/s41467-024-47331-3

Dommann J, Keiser J, Garneau J, Gandelin A, Casanova C, Keller P.M, Sayasone S, Vonaesch P, Schneeberger P.H.H. Exposure of gut bacterial isolates to the anthelminthic drugs, ivermectin and moxidectin, leads to antibiotic-like phenotypes of growth inhibition and adaptation. Commun Biol. 2024;7:1566. DOI: 10.1038/s42003-024-07135-z

Dommann J, Kerbl-Knapp J, Albertos Torres D, Egli A, Keiser J, Schneeberger P.H.H. A novel barcoded nanopore sequencing workflow of high-quality, full-length bacterial 16S amplicons for taxonomic annotation of bacterial isolates and complex microbial communities. mSystems. 2024;9(10):e0085924. DOI: 10.1128/msystems.00859-24

Emerson P.M, Evans D, Freeman M.C, Hanson C, Kalua K, Keiser J, Krolewiecki A, Leonard L, Levecke B, Matendechero S, Means A.R, Montresor A, Mupfasoni D, Pullan R.L, Rotondo L.A, Stephens M, Sullivan K.M, Walson J.L, Williams T, Utzinger J. Need for a paradigm shift in soil-transmitted helminthiasis control: targeting the right people, in the right place, and with the right drug(s). PLoS Negl Trop Dis. 2024;18(10):e0012521. DOI: 10.1371/journal.pntd.0012521

Fuchs N, Zimmermann R.A, Schwickert M, Gunkel A, Zimmer C, Meta M, Schwickert K, Keiser J, Häberli C, Kiefer W, Schirmeister T. Dual strategy to design new agents targeting Schistosoma mansoni: advancing phenotypic and SmCB1 inhibitors for improved efficacy. ACS Infect Dis. 2024;10(5):1664-1678. DOI: 10.1021/acsinfecdis.4c00020

González Cabrera D, Keiser J, Spangenberg T. Analysis of the physicochemical properties of anti-schistosomal compounds to identify next-generation leads. ACS Med Chem Lett. 2024;15(5):626-630. DOI: 10.1021/acsmedchemlett.4c00026

Gordon C.A, Utzinger J, Muhi S, Becker S.L, Keiser J, Khieu V, Gray D.J. Strongyloidiasis. Nat Rev Dis Primers. 2024;10:6. DOI: 10.1038/s41572-023-00490-x

Grolimund C.M, Utzinger J, Coulibaly J.T, Sayasone S, Ali S.M, Keiser J, Vounatsou P. Modeling transmission mechanism to infer treatment efficacy of different drugs and combination therapy against Trichuris trichiura. Sci Rep. 2024;14:23543. DOI: 10.1038/s41598-024-73164-7

Keiser J, Bouchery T. A step forward in the journey towards hookworm vaccines. Lancet Infect Dis. 2024;24(7):673-674. DOI: 10.1016/s1473-3099(24)00145-2

Kuevi D.N.O, Keiser J, Häberli C, Owusu-Senyah A.K, Ahiabu M.K. In vitro antischistosomal activity of Bridelia ferruginea, Clausena anisata, Khaya senegalensis, and Vernonia amygdalina. J Trop Med. 2024;2024(1):8074291. DOI: 10.1155/2024/8074291

Leas D.A, Keiser J, Charman S.A, Shackleford D.M, Jones J.O, Campbell M, Chen G, Katneni K, Patil R, Hu M, Pham T, Häberli C, Schulze T.T, Neville A.J, Wang X, Dong Y, Davis P.H, Vennerstrom J.L. Single-dose drug development candidate for schistosomiasis. ACS Infect Dis. 2024;10(11):3963-3972. DOI: 10.1021/acsinfecdis.4c00677

Lotz C.N, Krollenbrock A, Imhof L, Riscoe M, Keiser J. Robenidine derivatives as potential antischistosomal drug candidates. Int J Parasitol Drugs Drug Resist. 2024;25:100546. DOI: 10.1016/j.ijpddr.2024.100546

Palmeirim M.S, Hürlimann E, Beinamaryo P, Kyarisiima H, Nabatte B, Hattendorf J, Steinmann P, Keiser J. Efficacy and safety of albendazole alone versus albendazole in combination with ivermectin for the treatment of Trichuris trichiura infections: an open-label, randomized controlled superiority trial in south-western Uganda. PLoS Negl Trop Dis. 2024;18(11):e0012687. DOI: 10.1371/journal.pntd.0012687

Pillay-Fuentes Lorente V, Nwogu-Attah J.N, Steffens B, Bräm D, Sprecher V, Hofmann D, Buettcher M, Pillai G, Mouksassi S, Coulibaly J, Pfister M, Keiser J. Understanding drug exposure and Trichuris trichiura cure rates: a pharmacometric approach for albendazole-ivermectin co-medication in Tanzania and Côte d'Ivoire. Drugs R D. 2024;24(2):331-340. DOI: 10.1007/s40268-024-00476-4

Qian M.B, Keiser J, Utzinger J, Zhou X.N. Clonorchiasis and opisthorchiasis: epidemiology, transmission, clinical features, morbidity, diagnosis, treatment, and control. Clin Microbiol Rev. 2024;37(1):e0000923. DOI: 10.1128/cmr.00009-23

Ren R, Leas D.A, Häberli C, Cal M, Chen G, Katneni K, Dong Y, Kaiser M, Keiser J, Charman S.A, Vennerstrom J.L. Medium-ring keto bislactams with antischistosomal activity. J Med Chem. 2024;67(20):18235-18246. DOI: 10.1021/acs.jmedchem.4c01532

Shanley H.T, Taki A.C, Nguyen N, Wang T, Byrne J.J, Ang C.S, Leeming M.G, Nie S, Williamson N, Zheng Y, Young N.D, Korhonen P.K, Hofmann A, Chang B.C.H, Wells T.N.C, Häberli C, Keiser J, Jabbar A, Sleebs B.E, Gasser R.B. Structure-activity relationship and target investigation of 2-aryl quinolines with nematocidal activity. Int J Parasitol Drugs Drug Resist. 2024;24:100522. DOI: 10.1016/j.ijpddr.2024.100522

Sprecher V.P, Hofmann D, Savathdy V, Xayavong P, Norkhankhame C, Huy R, Khieu V, Sayasone S, Hattendorf J, Keiser J. Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial. Lancet Infect Dis. 2024;24(2):196-205. DOI: 10.1016/s1473-3099(23)00507-8

Stettler M, Lotz C, Probst A, Marreros N, Lundström-Stadelmann B, Frey C.F, Keiser J, Hofer A, Hoby S. Safety and pharmacokinetics of praziquantel in European pond turtles (Emys orbicularis). J Zoo Wildl Med. 2024;54(4):728-737. DOI: 10.1638/2023-0031

Taylor L, Ahmada A.A, Ali M.S, Ali S.M, Hattendorf J, Mohammed I.S, Keiser J. Efficacy and safety of emodepside compared with albendazole in adolescents and adults with hookworm infection in Pemba Island, Tanzania: a double-blind, superiority, phase 2b, randomised controlled trial. Lancet. 2024;404(10453):683-691. DOI: 10.1016/s0140-6736(24)01403-x